The Brain&Mind biocluster
Technological and clinical development programs, one community.
.png)
La Manufactures solutions for neuroscience
Brain&Mind is a Biocluster, i.e. an ecosystem bringing together a critical mass of scientific and medical expertise coupled with a community of innovative companies developing products and services in the fields of neurology, psychiatry and sensory disabilities.
Started in mid-2024, it is one of the main health investments of the France 2030 program, with nearly 100 million euros over 10 years.
Brain&Mind was created as an Association under the 1901 law, with around twenty co-founders sitting on its Board of Directors.
Our mission
Bringing together players in neuroscience innovation to more effectively transform discoveries into concrete solutions. To do this, our means of action are to:
Strengthening startups
By providing them with an environment conducive to the development of advanced technologies and by facilitating their access to strategic resources.
Improving clinical research methodologies
To optimize the chances of success of new drugs and medical technologies
Develop solutions
Scientifically validated for the prevention, diagnosis, prognosis, and therapeutic support of patients.
A place of synergy and impact
A real field of experimentation and collaboration where research, care and innovation converge. We co-create with hospitals, universities, startups, startups, manufacturers, manufacturers, patients and caregivers to transform scientific discoveries into concrete solutions that are quickly accessible to patients.
Brain&Mind governance
Les BrainMakers
Our team is mainly composed of people who agree to wear hoodies, with good technical expertise in neuroscience and entrepreneurship.
The questions that you may not have dared to ask
No, but we do better: We provide both financing (up to several hundreds of thousands of euros) and networks of experts and service providers to “de-risk” the project in the eyes of investors. This contribution is made without taking shares in the capital and on the basis of Success Fees, in a model co-constructed with Venture Capital firms.
If you are a startup or a research center, Nada. You are just committed to being an active participant who is able to receive help as well as to give help.
According to scientific studies, it makes it possible to become strong, beautiful, rich and intelligent. And at the very least, this ensures that you have:
- Fifteen hours of free advice
- Access (free) to all our events
- The possibility of offering structuring investments
- A structured relationship with scientific experts
- Access (for cheap) to meeting rooms, laboratories, workspaces
Pretty good, thanks. Brain&Mind does not deal with the upstream phases of pre-maturation, intellectual property, and technology transfer that fall under the responsibility of large organizations, universities and their subsidiaries. It arrives downstream of the academic value chain for “last-mile logistics” before industrialization. It thus allows the academic world to benefit from a tool to take one more step in the development of their inventions, and for the world of investment to take one less step in taking risks.
These platforms (clinical proteomics, digital biomarkers, etc.) are accessible without discrimination to all innovation actors. Their use can be done within the framework of scientific collaborations and in an open science logic, or in the form of a service (in which case they are accessible at market prices.)
Each of them is committed to devoting time and resources to the development of Brain&Mind. For example, they participate in “braincamps” to help map gaps in the R&D ecosystem. Several have also committed to financially supporting Brain&Mind projects.
Aucune donnée confidentielle sur les startups que nous accompagnons ou sur aucun des membres de Brain&Mind n’est transmise aux acteurs industriels. Lorsque l’un d’eux souhaite soutenir un projet particulier, il a alors accès – sous accord de confidentialité – aux informations nécessaires à son évaluation.
Through secure storage, strict confidentiality clauses, declarations of conflicts of interest and computer security audits.
Our actions, if they are effective, should enable more innovative companies to develop in the field of neuroscience and to carry out their clinical research programs in France. It is on these activities that, with our university hospital co-founders and French service companies, we will be able to value the fruits of our investments and guarantee our sustainability.
Yes. We will not enter into partnerships with companies that are controlled by authoritarian states or that make dual use of technology.
We also prohibit any development that is not in line with the principles of the French Neurotechnology Charter.